Pacific Edge posts $14.5m loss as it awaits US Medicare decisions

Pacific Edge posts $14.5m loss as it awaits US Medicare decisions
Pacific Edge chief executive Peter Meintjes says as each day passes, he feels more confident about a favourable decision from Novitas. (Image: Supplied)
John Anthony
Dunedin-headquartered cancer diagnostics company Pacific Edge has posted a $14.5 million after-tax loss for the six months to September 30.The NZX and ASX-listed company said it was awaiting outcomes of several events that had the potential to renew growth in Cxbladder, its urine-based genomic biomarker test for the detection and surveillance of bladder cancer. The events include:Novitas, the Medicare Administrative Contractor (MAC) with responsibility for Pacific Edge’s US lab, making a favourable policy decision on a Local Coverage...

More Markets

Aroa posts $1.5m HY loss, forecasts annual profit
Markets

Aroa posts $1.5m HY loss, forecasts annual profit

Auckland surgical products company is forecasting annual profit of between $2m to $6m.

Blis in the black
Markets

Blis in the black

Blis has reported an increase in revenue and earnings despite a patent dispute.

Gentrack hits $213m revenue, profit dips
Markets

Gentrack hits $213m revenue, profit dips

Software firm won't pay dividend as it plans for more growth in consolidating markets.

Asset Plus progresses towards wind-up
Property

Asset Plus progresses towards wind-up

The firm clears debt, issues a special dividend, moves towards wind-up.